
Sign up to save your podcasts
Or


Dame Jane Osbourn, chief scientific officer at Alchemab Therapeutics, speaks with Ahuva Nissim, antibody and therapeutic engineering professor at Queen Mary University of London William Harvey Research Institute, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent protective antibodies. Osbourn talks about the most inspiring mentors of her career, her interest in immunological resiliency, the importance of studying neurodegenerative diseases, and her drug discovery work at Alchemab Therapeutics. Finally, she talks about the technological advancements she hopes will move precision medicine forward in the near and distant future.
By Cambridge Healthtech Institute4.8
2525 ratings
Dame Jane Osbourn, chief scientific officer at Alchemab Therapeutics, speaks with Ahuva Nissim, antibody and therapeutic engineering professor at Queen Mary University of London William Harvey Research Institute, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent protective antibodies. Osbourn talks about the most inspiring mentors of her career, her interest in immunological resiliency, the importance of studying neurodegenerative diseases, and her drug discovery work at Alchemab Therapeutics. Finally, she talks about the technological advancements she hopes will move precision medicine forward in the near and distant future.

26,248 Listeners

124 Listeners

323 Listeners

14,333 Listeners

61 Listeners

976 Listeners

21 Listeners

10 Listeners